Two feet on the membrane: Uptake of clostridial neurotoxins

Current Topics in Microbiology and Immunology

Volumn 406, Issue , 2017, Pages 1-37

  Rummel, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; CLOSTRIDIUM NEUROTOXIN; CLOSTRIDIUM TOXIN; GANGLIOSIDE; MEMBRANE PROTEIN; NEUROTRANSMITTER; SYNAPTIC VESICLE GLYCOPROTEIN 2; SYNAPTOTAGMIN I; SYNAPTOTAGMIN II; TETANUS TOXIN; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PROTEIN BINDING;

ACIDIFICATION; BETA SHEET; BINDING SITE; CELL MEMBRANE; CHOLINERGIC NERVE CELL; ENDOCYTOSIS; FLACCID PARALYSIS; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; RESPIRATORY FAILURE; SPASTIC PARESIS; SYNAPSE VESICLE; TOXICOKINETICS; TOXIN ANALYSIS; TOXIN STRUCTURE; METABOLISM;

BOTULINUM TOXINS; ENDOCYTOSIS; HUMANS; NEUROTRANSMITTER AGENTS; PROTEIN BINDING; SYNAPTIC VESICLES; TETANUS TOXIN;

EID: 85037051950     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2016_48     Document Type: Chapter

References (205)

1. Angstrom J, Teneberg S, Karlsson KA (1994) Delineation and comparison of ganglioside-binding epitopes for the toxins of vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for overlapping epitopes. Proc Natl Acad Sci U S A 91(25):11859–11863.
2. Bajjalieh SM, Peterson K, Shinghal R, Scheller RH (1992) SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257(5074):1271–1273.
3. Bajjalieh SM, Peterson K, Linial M, Scheller RH (1993) Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A 90(6):2150–2154.
4. Baldwin MR, Barbieri JT (2007) Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry 46(11):3200–3210.
5. Barash JR, Arnon SS (2014) A novel strain of Clostridium botulinum that produces type B and type H Botulinum Toxins. J Infect Dis 209(2):183–191.
6. Bengtson IA (1922) Preliminary note on a toxin-producing anaerobe isolated from larvae of the green fly Lucilia caesar. US Public Health Rep 37:164–170.
7. Bengtson IA (1923) A toxin-producing anaerobe isolated principally from fly larvae. Its relation to the organisms hitherto known to be the causative factors in the production of botulism. US Public Health Reports 38:340–344.
8. Benoit RM, Frey D, Hilbert M, Kevenaar JT, Wieser MM, Stirnimann CU, McMillan D, Ceska T, Lebon F, Jaussi R, Steinmetz MO, Schertler GF, Hoogenraad CC, Capitani G, Kammerer RA (2014) Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 505(7481):108–111.
9. Benson MA, Fu Z, Kim JJ, Baldwin MR (2011) Unique ganglioside recognition strategies for clostridial neurotoxins. J Biol Chem 286(39):34015–34022.
10. Bercsenyi K, Giribaldi F, Schiavo G (2013) The Elusive Compass of Clostridial Neurotoxins: Deciding When and Where to Go? In: Rummel A, Binz T (eds) Botulinum neurotoxins. Springer-Verlag, Berlin Heidelberg, pp 91–113.
11. Bercsenyi K, Schmieg N, Bryson JB, Wallace M, Caccin P, Golding M, Zanotti G, Greensmith L, Nischt R, Schiavo G (2014) Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus. Science 346(6213):1118–1123.
12. Bergey GK, Bigalke H, Nelson PG (1987) Differential effects of tetanus toxin on inhibitory and excitatory synaptic transmission in mammalian spinal cord neurons in culture: a presynaptic locus of action for tetanus toxin. J Neurophysiol 57(1):121–131.
13. Berntsson RP, Peng L, Svensson LM, Dong M, Stenmark P (2013a) Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II. Structure 21(9):1602–1611.
14. Berntsson RP, Peng L, Dong M, Stenmark P (2013b) Structure of dual receptor binding to botulinum neurotoxin B. Nat Commun 28(4):2058.
15. Bigalke H, Muller H, Dreyer F (1986) Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. Toxicon 24(11–12):1065–1074.
16. Binz T (2013) Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol 364:139–157.
17. Binz T, Kurazono H, Popoff MR, Eklund MW, Sakaguchi G, Kozaki S, Krieglstein K, Henschen A, Gill DM, Niemann H (1990) Nucleotide sequence of the gene encoding clostridium botulinum neurotoxin type D. Nucleic Acids Res 18(18):5556.
18. Black JD, Dolly JO (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103(2):535–544.
19. Bohnert S, Schiavo G (2005) Tetanus toxin is transported in a novel neuronal compartment characterized by a specialized pH regulation. J Biol Chem 280(51):42336–42344.
20. Brunger AT, Rummel A (2009) Receptor and substrate interactions of clostridial neurotoxins. Toxicon 54(5):550–560.
21. Bullens RW, O’Hanlon GM, Wagner E, Molenaar PC, Furukawa K, Furukawa K, Plomp JJ, Willison HJ (2002) Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci 22(16):6876–6884.
22. Burke GS (1919) Notes on Bacillus botulinus. J Bacteriol 4(5):555–701.
23. Campbell K, Collins MD, East AK (1993) Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins. Biochim Biophys Acta 1216(3):487–491.
24. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444(7122):1096–1100.
25. Chang WP, Südhof TC (2009) SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis. J Neurosci 29(4):883–897.
26. Chapman ER (2002) Synaptotagmin: a Ca(2+) sensor that triggers exocytosis? Nat Rev Mol Cell Biol 3(7):498–508.
27. Chen Y, Korkeala H, Aarnikunnas J, Lindstrom M (2007) Sequencing the botulinum neurotoxin gene and related genes in Clostridium botulinum type E strains reveals orfx3 and a novel type E neurotoxin subtype. J Bacteriol 189(23):8643–8650.
28. Chen C, Baldwin MR, Barbieri JT (2008) Molecular basis for tetanus toxin coreceptor interactions. Biochemistry 47(27):7179–7186.
29. Chen C, Fu Z, Kim JJ, Barbieri JT, Baldwin MR (2009) Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem 284(39):26569–26577.
30. Cosman M, Lightstone FC, Krishnan VV, Zeller L, Prieto MC, Roe DC, Balhorn R (2002) Identification of novel small molecules that bind to two different sites on the surface of tetanus toxin C fragment. Chem Res Toxicol 15(10):1218–1228.
31. Critchley DR, Habig WH, Fishman PH (1986) Reevaluation of the role of gangliosides as receptors for tetanus toxin. J Neurochem 47(1):213–222.
32. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26(4):1303–1313.
33. Debaisieux S, Encheva V, Chakravarty P, Snijders AP, Schiavo G (2016) Analysis of signaling endosome composition and dynamics using SILAC in embryonic stem cell-derived neurons. Mol Cell Proteomics 15(2):542–557.
34. Deinhardt K, Berninghausen O, Willison HJ, Hopkins CR, Schiavo G (2006a) Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol 174(3):459–471.
35. Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G (2006b) Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron 52(2):293–305.
36. Dolly JO, Black J, Williams RS, Melling J (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307(5950):457–460.
37. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162(7):1293–1303.
38. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312(5773):592–596.
39. Dong M, Tepp WH, Liu H, Johnson EA, Chapman ER (2007) Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol 179(7):1511–1522.
40. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19(12):5226–5237.
41. Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2014) Molecular characterization of a novel botulinum neurotoxin type h gene. J Infect Dis 209(2):192–202.
42. East AK, Richardson PT, Allaway D, Collins MD, Roberts TA, Thompson DE (1992) Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Microbiol Lett 75(2–3):225–230.
43. East AK, Bhandari M, Hielm S, Collins MD (1998) Analysis of the botulinum neurotoxin type F gene clusters in proteolytic and nonproteolytic Clostridium botulinum and Clostridium barati. Curr Microbiol 37(4):262–268.
44. Eisel U, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Habermann E, Niemann H (1986) Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. Embo J 5(10):2495–2502.
45. C -fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 275(12):8889–8894.
46. Eswaramoorthy S, Kumaran D, Swaminathan S (2001) Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B. Acta Crystallogr D Biol Crystallogr 57(Pt 11):1743–1746.
47. Eswaramoorthy S, Sun J, Li H, Singh BR, Swaminathan S (2015) Molecular assembly of Clostridium botulinum progenitor M complex of type E. Sci Rep 5:17795.
48. Evinger C, Erichsen JT (1986) Transsynaptic retrograde transport of fragment C of tetanus toxin demonstrated by immunohistochemical localization. Brain Res 380(2):383–388.
49. Fischer A, Mushrush DJ, Lacy DB, Montal M (2008a) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4(12):e1000245.
50. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M (2008b) Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem 283(7):3997–4003.
51. Fishman PS, Carrigan DR (1987) Retrograde transneuronal transfer of the C-fragment of tetanus toxin. Brain Res 406(1–2):275–279.
52. C -fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J Biol Chem 276(34):32274–32281.
53. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48(24):5631–5641.
54. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25(1):107–116.
55. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD (2011) Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel 24(3):321–331.
56. Geppert M, Archer BT 3rd, Südhof TC (1991) Synaptotagmin II. A novel differentially distributed form of synaptotagmin. J Biol Chem 266(21):13548–13552.
57. Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46(1):86–94.
58. Gimenez DF, Ciccarelli AS (1970) Another type of clostridium botulinum. Zentralblatt für Bakteriologie [Orig A]. 215(2):221–224.
59. Ginalski K, Venclovas C, Lesyng B, Fidelis K (2000) Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett 482(1–2):119–124.
60. Giordani F, Fillo S, Anselmo A, Palozzi AM, Fortunato A, Gentile B, Azarnia Tehran D, Ciammaruconi A, Spagnolo F, Pittiglio V, Anniballi F, Auricchio B, De Medici D, Lista F (2015) Genomic characterization of Italian Clostridium botulinum group I strains. Infect Genet Evol 36:62–71.
61. Gonzalez-Escalona N, Thirunavukkarasu N, Singh A, Toro M, Brown EW, Zink D, Rummel A, Sharma SK (2014) Draft genome sequence of bivalent Clostridium botulinum Strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA mosaic type. Genome Announc 2(6)
62. Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335(6071):977–981.
63. Hauser D, Eklund MW, Kurazono H, Binz T, Niemann H, Gill DM, Boquet P, Popoff MR (1990) Nucleotide sequence of Clostridium botulinum C1 neurotoxin. Nucleic Acids Res 18(16):4924.
64. Hazel EL (1937) A strain of B. botulinus not classified as type A, B, or C. J Infect Dis 60(3):260–264.
65. Herreros J, Ng T, Schiavo G (2001) Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons. Mol Biol Cell 12(10):2947–2960.
66. Hill KK, Smith TJ (2013) Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364:1–20.
67. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD (2007) Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 189(3):818–832.
68. Hughes R, Whaler BC (1962) Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol 160:221–233.
69. Hutson RA, Collins MD, East AK, Thompson DE (1994) Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr Microbiol 28(2):101–110.
70. Hutson RA, Zhou Y, Collins MD, Johnson EA, Hatheway CL, Sugiyama H (1996) Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences. J Biol Chem 271(18):10786–10792.
71. Ihara H, Kohda T, Morimoto F, Tsukamoto K, Karasawa T, Nakamura S, Mukamoto M, Kozaki S (2003) Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity. Biochim Biophys Acta 1625(1):19–26.
72. Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94(4):1279–1290.
73. Jayaraman S, Eswaramoorthy S, Kumaran D, Swaminathan S (2005) Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin. Proteins 61(2):288–295.
74. Jin R, Rummel A, Binz T, Brunger AT (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444(7122):1092–1095.
75. Kalb SR, Baudys J, Rees JC, Smith TJ, Smith LA, Helma CH, Hill K, Kull S, Kirchner S, Dorner MB, Dorner BG, Pirkle JL, Barr JR (2012) De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal Bioanal Chem 403(1):215–226.
76. Kamata Y, Kozaki S, Sakaguchi G, Iwamori M, Nagai Y (1986) Evidence for direct binding of Clostridium botulinum type E derivative toxin and its fragments to gangliosides and free fatty acids. Biochem Biophys Res Commun 140(3):1015–1019.
77. Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, Barbieri JT (2010) Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 49(37):8117–8126.
78. Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT (2012) Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J Biol Chem 287(48):40806–40816.
79. Kawai H, Allende ML, Wada R, Kono M, Sango K, Deng C, Miyakawa T, Crawley JN, Werth N, Bierfreund U, Sandhoff K, Proia RL (2001) Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J Biol Chem 276(10):6885–6888.
80. Keller JE, Cai F, Neale EA (2004) Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43(2):526–532.
81. Kitamura M, Iwamori M, Nagai Y (1980) Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta 628(3):328–335.
82. Kitamura M, Takamiya K, Aizawa S, Furukawa K (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim Biophys Acta 1441(1):1–13.
83. Kitamura M, Igimi S, Furukawa K, Furukawa K (2005) Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins. Biochim Biophys Acta 1741(1–2):1–3.
84. Kitasato S (1889) Über den Tetanusbacillus. Z für Hygiene und Infektionskrankheiten 7:225–234.
85. Kozaki S, Ogasawara J, Shimote Y, Kamata Y, Sakaguchi G (1987) Antigenic structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebroside, and free fatty acids. Infect Immun 55(12):3051–3056.
86. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S (1998) Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 25(2):91–99.
87. Kranz G, Paul A, Voller B, Posch M, Windischberger C, Auff E, Sycha T (2011) Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol 164(1):176–181.
88. Kroken AR, Karalewitz AP, Fu Z, Kim JJ, Barbieri JT (2011a) Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J Biol Chem 286(30):26828–26837.
89. Kroken AR, Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT (2011b) Unique ganglioside binding by botulinum neurotoxins C and D-SA. FEBS J 278(23):4486–4496.
90. Kull S, Schulz KM, Weisemann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dorner MB, Barr JR, Rummel A, Dorner BG (2015) Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS ONE 10(2):e0116381.
91. Kumaran D, Eswaramoorthy S, Furey W, Navaza J, Sax M, Swaminathan S (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386(1):233–245.
92. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10):898–902.
93. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 112(Pt 16):2715–2724.
94. Landmann G (1904) Über die Ursache der Darmstädter Bohnenvergiftung. Hygienische Rundschau. 1904; 4:10.
95. Lawrence G, Wang J, Chion CK, Aoki KR, Dolly JO (2007) Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E. J Pharmacol Exp Ther 320(1):410–418.
96. Lazarovici P, Yavin E (1986) Affinity-purified tetanus neurotoxin interaction with synaptic membranes: properties of a protease-sensitive receptor component. Biochemistry 25(22):7047–7054.
97. Leuchs J (1910) Beiträge zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus. Z für Hygiene und Infektionskrankheiten 65(1):55–84.
98. Li JY, Jahn R, Dahlstrom A (1994) Synaptotagmin I is present mainly in autonomic and sensory neurons of the rat peripheral nervous system. Neuroscience 63(3):837–850.
99. Lightstone FC, Prieto MC, Singh AK, Piqueras MC, Whittal RM, Knapp MS, Balhorn R, Roe DC (2000) Identification of novel small molecule ligands that bind to tetanus toxin. Chem Res Toxicol 13(5):356–362.
100. Louch HA, Buczko ES, Woody MA, Venable RM, Vann WF (2002) Identification of a binding site for ganglioside on the receptor binding domain of tetanus toxin. Biochemistry 41(46):13644–13652.
101. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580(8):2011–2014.
102. Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T (2013) Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J 453(1):37–47.
103. Mahrhold S, Bergstrom T, Stern D, Dorner BG, Astot C, Rummel A (2016) Only the complex N559-glycan in SV2C mediates high affinity binding to botulinum neurotoxin serotype A1. Biochem J.
104. Marxen P, Bigalke H (1989) Tetanus toxin: inhibitory action in chromaffin cells is initiated by specified types of gangliosides and promoted in low ionic strength solution. Neurosci Lett 107(1–3):261–266.
105. Marxen P, Fuhrmann U, Bigalke H (1989) Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon 27(8):849–859.
106. Marxen P, Erdmann G, Bigalke H (1991) The translocation of botulinum A neurotoxin by chromaffin cells is promoted in low ionic strength solution and is insensitive to trypsin. Toxicon 29(2):181–189.
107. Maslanka SE, Luquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA (2016) A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and Is neutralized with serotype A Antitoxin. J Infect Dis 213(3):379–385.
108. Mazuet C, Sautereau J, Legeay C, Bouchier C, Bouvet P, Popoff MR (2015) An atypical outbreak of food-borne botulism due to Clostridium botulinum types B and E from ham. J Clin Microbiol 53(2):722–726.
109. Meyer KF, Gunnison JB (1929) South African cultures of Clostridium botulinum and Cl. parabotulinum with a description of Cl. botulinum type D, N. SP. J Infect Dis 45:106–118.
110. Møller V, Scheibel I (1960) Preliminary report on the isolation of an apparently new type of CI. botulinum. Acta Pathol Microbiol Scand 48:80.
111. Montecucco C (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11(8):314–317.
112. Moriishi K, Syuto B, Kubo S, Oguma K (1989) Molecular diversity of neurotoxins from Clostridium botulinum type D strains. Infect Immun 57(9):2886–2891.
113. Moriishi K, Koura M, Abe N, Fujii N, Fujinaga Y, Inoue K, Ogumad K (1996a) Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochim Biophys Acta 1307(2):123–126.
114. Moriishi K, Koura M, Fujii N, Fujinaga Y, Inoue K, Syuto B, Oguma K (1996b) Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types C1 and D, and PCR detection of this gene from Clostridium botulinum type C organisms. Appl Environ Microbiol 62(2):662–667.
115. Mullaney BP, Pallavicini MG, Marks JD (2001) Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun 69(10):6511–6514.
116. Munro P, Kojima H, Dupont JL, Bossu JL, Poulain B, Boquet P (2001) High sensitivity of mouse neuronal cells to tetanus toxin requires a GPI-anchored protein. Biochem Biophys Res Commun 289(2):623–629.
117. Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C (2009) The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun 380(1):76–80.
118. Niemann H, Blasi J, Jahn R (1994) Clostridial neurotoxins: new tools for dissecting exocytosis. Trends Cell Biol 4(5):179–185.
119. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, Takahashi M, Kozaki S (1994) Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269(14):10498–10503.
120. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, Kozaki S (1996a) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378(3):253–257.
121. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sekiguchi M, Takahashi M, Kozaki S (1996b) Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci Lett 208(2):105–108.
122. Nowack A, Yao J, Custer KL, Bajjalieh SM (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol 299(5):C960–C967.
123. Nuemket N, Tanaka Y, Tsukamoto K, Tsuji T, Nakamura K, Kozaki S, Yao M, Tanaka I (2011) Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism. Biochem Biophys Res Commun 411(2):433–439.
124. Ochanda JO, Syuto B, Ohishi I, Naiki M, Kubo S (1986) Binding of Clostridium botulinum neurotoxin to gangliosides. J Biochem (Tokyo) 100(1):27–33.
125. O’Grady P, Thai TC, Saito H (1998) The laminin-nidogen complex is a ligand for a specific splice isoform of the transmembrane protein tyrosine phosphatase LAR. J Cell Biol 141(7):1675–1684.
126. Osborne RH, Bradford HF (1973) Tetanus toxin inhibits amino acid release from nerve endings in vitro. Nat New Biol 244(135):157–158.
127. Pang ZP, Melicoff E, Padgett D, Liu Y, Teich AF, Dickey BF, Lin W, Adachi R, Sudhof TC (2006) Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromuscular synapses. J Neurosci 26(52):13493–13504.
128. Peck MW, Smith TJ (2016) Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. J Bacteriol.
129. Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, Johnson EA (2016) Purification and characterization of botulinum neurotoxin FA from a genetically modified clostridium botulinum strain. mSphere 1(1):e00100–e00115.
130. Peng L, Tepp WH, Johnson EA, Dong M (2011) Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog 7(3):e1002008.
131. Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, Dong M (2012) Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci 125(Pt 13):3233–3242.
132. Perin MS, Fried VA, Mignery GA, Jahn R, Südhof TC (1990) Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. Nature 345(6272):260–263.
133. Pierce EJ, Davison MD, Parton RG, Habig WH, Critchley DR (1986) Characterization of tetanus toxin binding to rat brain membranes. Evidence for a high-affinity proteinase-sensitive receptor. Biochem J 236(3):845–852.
134. Pirazzini M, Rossetto O, Bolognese P, Shone CC, Montecucco C (2011) Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell Microbiol 13(11):1731–1743.
135. Pirazzini M, Henke T, Rossetto O, Mahrhold S, Krez N, Rummel A, Montecucco C, Binz T (2013) Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett 587(23):3831–3836.
136. Poulet S, Hauser D, Quanz M, Niemann H, Popoff MR (1992) Sequences of the botulinal neurotoxin E derived from Clostridium botulinum type E (strain Beluga) and Clostridium butyricum (strains ATCC 43181 and ATCC 43755). Biochem Biophys Res Commun 183(1):107–113.
137. Raphael BH, Choudoir MJ, Luquez C, Fernandez R, Maslanka SE (2010) Sequence diversity of genes encoding botulinum neurotoxin type F. Appl Environ Microbiol 76(14):4805–4812.
138. Raphael BH, Lautenschlager M, Kalb SR, de Jong LI, Frace M, Luquez C, Barr JR, Fernandez RA, Maslanka SE (2012) Analysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype. BMC Microbiol 12:245.
139. Rummel A (2013) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. In: Rummel A, Binz T (eds) Botulinum neurotoxins. Springer-Verlag, Berlin Heidelberg, pp 61–90.
140. Rummel A (2015) The long journey of botulinum neurotoxins into the synapse. Toxicon 107(Pt A):9–24.
141. CC -domain of tetanus neurotoxin are required for toxicity. J Mol Biol 326(3):835–847.
142. Rummel A, Karnath T, Henke T, Bigalke H, Binz T (2004a) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem 279(29):30865–30870.
143. CC -domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51(3):631–643.
144. Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, Sandhoff K, Proia RL, Acharya KR, Bigalke H, Binz T (2007) Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 104(1):359–364.
145. Rummel A, Häfner K, Mahrhold S, Darashchonak N, Holt M, Jahn R, Beermann S, Karnath T, Bigalke H, Binz T (2009) Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem 110(6):1942–1954.
146. Santos-Buelga JA, Collins MD, East AK (1998) Characterization of the genes encoding the botulinum neurotoxin complex in a strain of Clostridium botulinum producing type B and F neurotoxins. Curr Microbiol 37(5):312–318.
147. Schengrund CL, DasGupta BR, Ringler NJ (1991) Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof. J Neurochem 57(3):1024–1032.
148. Schiavo G, Ferrari G, Rossetto O, Montecucco C (1991) Tetanus toxin receptor. Specific cross-linking of tetanus toxin to a protein of NGF-differentiated PC 12 cells. FEBS Lett 290(1–2):227–230.
149. Schmitt A, Dreyer F, John C (1981) At least three sequential steps are involved in the tetanus toxin-induced block of neuromuscular transmission. Naunyn Schmiedebergs Arch Pharmacol 317(4):326–330.
150. Schmitt J, Karalewitz A, Benefield DA, Mushrush DJ, Pruitt RN, Spiller BW, Barbieri JT, Lacy DB (2010) Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry 49(25):5200–5205.
151. Sebaihia M, Peck MW, Minton NP, Thomson NR, Holden MT, Mitchell WJ, Carter AT, Bentley SD, Mason DR, Crossman L, Paul CJ, Ivens A, Wells-Bennik MH, Davis IJ, Cerdeno-Tarraga AM, Churcher C, Quail MA, Chillingworth T, Feltwell T, Fraser A, Goodhead I, Hance Z, Jagels K, Larke N, Maddison M, Moule S, Mungall K, Norbertczak H, Rabbinowitsch E, Sanders M, Simmonds M, White B, Whithead S, Parkhill J (2007) Genome sequence of a proteolytic (group I) clostridium botulinum strain hall A and comparative analysis of the clostridial genomes. Genome Res 17(7):1082–1092.
152. Shapiro RE, Specht CD, Collins BE, Woods AS, Cotter RJ, Schnaar RL (1997) Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand. J Biol Chem 272(48):30380–30386.
153. Sikorra S, Skiba M, Dorner MB, Weisemann J, Weil M, Valdezate S, Davletov B, Rummel A, Dorner BG, Binz T (2016) Botulinum neurotoxin F subtypes cleaving the VAMP-2 Q58-K59 peptide bond exhibit unique catalytic properties and substrate specificities. Biochemistry.
154. Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212(1):16–21.
155. Simpson LL (1982) A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther 223(3):695–701.
156. Simpson LL (1984a) Botulinum toxin and tetanus toxin recognize similar membrane determinants. Brain Res 305(1):177–180.
157. Simpson LL (1984b) The binding fragment from tetanus toxin antagonizes the neuromuscular blocking actions of botulinum toxin. J Pharmacol Exp Ther 229(1):182–187.
158. Simpson LL (1985) Pharmacological experiments on the binding and internalization of the 50,000 dalton carboxyterminus of tetanus toxin at the cholinergic neuromuscular junction. J Pharmacol Exp Ther 234(1):100–105.
159. Simpson LL, Rapport MM (1971a) Ganglioside inactivation of botulinum toxin. J Neurochem 18(7):1341–1343.
160. Simpson LL, Rapport MM (1971b) The binding of botulinum toxin to membrane lipids: sphingolipids, steroids and fatty acids. J Neurochem 18(9):1751–1759.
161. Sinha K, Box M, Lalli G, Schiavo G, Schneider H, Groves M, Siligardi G, Fairweather N (2000) Analysis of mutants of tetanus toxin Hc fragment: ganglioside binding, cell binding and retrograde axonal transport properties. Mol Microbiol 37(5):1041–1051.
162. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73(9):5450–5457.
163. Smith TJ, Hill KK, Xie G, Foley BT, Williamson CH, Foster JT, Johnson SL, Chertkov O, Teshima H, Gibbons HS, Johnsky LA, Karavis MA, Smith LA (2015a) Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes. Infect Genet Evol 30:102–113.
164. Smith TJ, Hill KK, Raphael BH (2015b) Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol 166(4):290–302.
165. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4(8):e1000129.
166. Stenmark P, Dong M, Dupuy J, Chapman ER, Stevens RC (2010) Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J Mol Biol 397(5):1287–1297.
167. Strotmeier J, Lee K, Völker AK, Mahrhold S, Zong Y, Zeiser J, Zhou J, Pich A, Bigalke H, Binz T, Rummel A, Jin R (2010) Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem J 431(2):207–216.
168. Strotmeier J, Gu S, Jutzi S, Mahrhold S, Zhou J, Pich A, Eichner T, Bigalke H, Rummel A, Jin R, Binz T (2011) The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol Microbiol 81(1):143–156.
169. Strotmeier J, Willjes G, Binz T, Rummel A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586(4):310–313.
170. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A (2014) Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett 588(7):1087–1093.
171. Stryker E, Johnson KG (2007) LAR, liprin alpha and the regulation of active zone morphogenesis. J Cell Sci 120(Pt 21):3723–3728.
172. Sudhof TC (2013) A molecular machine for neurotransmitter release: synaptotagmin and beyond. Nat Med 19(10):1227–1231.
173. Südhof TC (2002) Synaptotagmins: why so many? J Biol Chem 277(10):7629–7632.
174. Sun S, Suresh S, Liu H, Tepp WH, Johnson EA, Edwardson JM, Chapman ER (2011) Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10(3):237–247.
175. Sutton JM, Chow-Worn O, Spaven L, Silman NJ, Hallis B, Shone CC (2001) Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones. FEBS Lett 493(1):45–59.
176. Swaminathan S, Eswaramoorthy S (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7(8):693–699.
177. Takamizawa K, Iwamori M, Kozaki S, Sakaguchi G, Tanaka R, Takayama H, Nagai Y (1986) TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett 201(2):229–232.
178. Thompson DE, Brehm JK, Oultram JD, Swinfield TJ, Shone CC, Atkinson T, Melling J, Minton NP (1990) The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem 189(1):73–81.
179. Thompson DE, Hutson RA, East AK, Allaway D, Collins MD, Richardson PT (1993) Nucleotide sequence of the gene coding for Clostridium barati type F neurotoxin: comparison with other clostridial neurotoxins. FEMS Microbiol Lett 108(2):175–182.
180. Tsukamoto K, Kohda T, Mukamoto M, Takeuchi K, Ihara H, Saito M, Kozaki S (2005) Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem 280(42):35164–35171.
181. Tsukamoto K, Kozai Y, Ihara H, Kohda T, Mukamoto M, Tsuji T, Kozaki S (2008) Identification of the receptor-binding sites in the carboxyl-terminal half of the heavy chain of botulinum neurotoxin types C and D. Microb Pathog 44(6):484–493.
182. Tsukamoto K, Ozeki C, Kohda T, Tsuji T (2015) CRISPR/Cas9-mediated genomic deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 gene in murine P19 Embryonal carcinoma cells results in low sensitivity to botulinum Neurotoxin type C. PLoS ONE 10(7):e0132363.
183. van Ermengem EP (1897) Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z für Hygiene und Infektionskrankheiten 26(1):1–56.
184. van Heyningen WE (1959) Tentative identification of the tetanus toxin receptor in nervous tissue. J Gen Microbiol 20:810–820.
185. van Heyningen WE, Miller PA (1961) The fixation of tetanus toxin by ganglioside. J Gen Microbiol 24:107–119.
186. Verderio C, Coco S, Rossetto O, Montecucco C, Matteoli M (1999) Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J Neurochem 73(1):372–379.
187. Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R (2010) SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66(6):884–895.
188. Wangroongsarb P, Kohda T, Jittaprasartsin C, Suthivarakom K, Kamthalang T, Umeda K, Sawanpanyalert P, Kozaki S, Ikuta K (2014) Molecular characterization of Clostridium botulinum isolates from foodborne outbreaks in Thailand, 2010. PLoS ONE 9(1):e77792.
189. Weedmark KA, Lambert DL, Mabon P, Hayden KL, Urfano CJ, Leclair D, Van Domselaar G, Austin JW, Corbett CR (2014) Two novel toxin variants revealed by whole-genome sequencing of 175 Clostridium botulinum type E strains. Appl Environ Microbiol 80(20):6334–6345.
190. Weisemann J, Stern D, Mahrhold S, Dorner BG, Rummel A (2016) Botulinum neurotoxin serotype a recognizes its protein receptor SV2 by a different mechanism than botulinum neurotoxin B synaptotagmin. Toxins. 8(5):154.
191. Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP (1992a) Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol 58(8):2345–2354.
192. Whelan SM, Elmore MJ, Bodsworth NJ, Atkinson T, Minton NP (1992b) The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene. Eur J Biochem 204(2):657–667.
193. Willems A, East AK, Lawson PA, Collins MD (1993) Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Res Microbiol 144(7):547–556.
194. Williamson LC, Bateman KE, Clifford JC, Neale EA (1999) Neuronal sensitivity to tetanus toxin requires gangliosides. J Biol Chem 274(35):25173–25180.
195. Willjes G, Mahrhold S, Strotmeier J, Eichner T, Rummel A, Binz T (2013) Botulinum neurotoxin G binds synaptotagmin-II in a mode similar to that of serotype B: tyrosine 1186 and lysine 1191 cause its lower affinity. Biochemistry 52(22):3930–3938.
196. Xu T, Bajjalieh SM (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3(8):691–698.
197. Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM (2010) Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci 30(16):5569–5578.
198. Yao G, Zhang S, Mahrhold S, Lam KH, Stern D, Bagramyan K, Perry K, Kalkum M, Rummel A, Dong M, Jin R (2016) N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol 23(7):656–662.
199. Yeh FL, Dong M, Yao J, Tepp WH, Lin G, Johnson EA, Chapman ER (2010) SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog 6(11):e1001207.
200. Yokosawa N, Kurokawa Y, Tsuzuki K, Syuto B, Fujii N, Kimura K, Oguma K (1989) Binding of Clostridium botulinum type C neurotoxin to different neuroblastoma cell lines. Infect Immun 57(1):272–277.
201. Yowler BC, Schengrund CL (2004) Botulinum neurotoxin a changes conformation upon binding to ganglioside GT1b. Biochemistry 43(30):9725–9731.
202. Yowler BC, Kensinger RD, Schengrund CL (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem 277(36):32815–32819.
203. Zhang Y, Varnum SM (2012) The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides. Biochimie 94(3):920–923.
204. Zhang Y, Buchko GW, Qin L, Robinson H, Varnum SM (2011) Crystal structure of the receptor binding domain of the botulinum C-D mosaic neurotoxin reveals potential roles of lysines 1118 and 1136 in membrane interactions. Biochem Biophys Res Commun 404(1):407–412.
205. Zornetta I, Azarnia Tehran D, Arrigoni G, Anniballi F, Bano L, Leka O, Zanotti G, Binz T, Montecucco C (2016) The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep 6:30257.